17:25 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Ergomed's PeproStat meets in Phase II for intraoperative surgical bleeding

In October, Ergomed plc (LSE:ERGO) reported top-line data from a Phase II trial to treat intraoperative surgical bleeding in 169 patients undergoing liver/soft tissue, vascular or spinal surgery showing that PeproStat met the primary endpoint...
20:33 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest inhibiting fibrinogen could help treat MS. In postmortem brain tissue samples from MS patients, levels of perivascular fibrinogen were higher in chronic MS lesions than in...
15:08 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Ergomed completes enrollment in Ph IIb of PeproStat

Ergomed plc (LSE:ERGO) completed enrollment of >160 patients undergoing liver, soft tissue, vascular or spinal surgery in a Phase IIb trial of PeproStat to treat intraoperative surgical bleeding. The primary endpoint for the double-blind, placebo-controlled,...
23:27 , Aug 17, 2017 |  BC Innovations  |  Targets & Mechanisms

GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development. The...
20:31 , Jun 16, 2017 |  BC Week In Review  |  Company News

CSL buying majority stake in Chinese plasma company

CSL Ltd. (ASX:CSL) said it is acquiring an 80% stake in plasma therapy company Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide) for $352 million. Ruide is a subsidiary of Humanwell Healthcare Group...
20:18 , Jun 13, 2017 |  BC Extra  |  Company News

CSL buying majority stake in Chinese plasma company

CSL Ltd. (ASX:CSL) said it is acquiring an 80% stake in plasma therapy company Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide) for $352 million. Ruide is a subsidiary of Humanwell Healthcare Group...
00:26 , Apr 15, 2017 |  BioCentury  |  Product Development

Outside factors

This year could see the first regulatory submission from a coming wave of new therapies for hemophilia prophylaxis that do not simply replace missing clotting factors, which has been the standard for care for decades....
00:59 , Mar 30, 2017 |  BC Week In Review  |  Clinical News

PeproStat: Ph II started

Ergomed began a double-blind, placebo-controlled, European Phase IIb trial to evaluate topical PeproStat in about 120 patients undergoing liver, soft tissue, vascular or spinal surgery. Ergomed plc (LSE:ERGO), Guilford, U.K.  Product: PeproStat  Business: Hematology  Molecular target: Fibrinogen  Description: Peptide-based hemostat...
07:00 , Sep 12, 2016 |  BC Extra  |  Politics & Policy

FDA issues final guidance on COPD biomarker

FDA issued final guidance outlining its recommendations on the use of plasma fibrinogen as a prognostic biomarker for patients with chronic obstructive pulmonary disease (COPD) who are at high risk for exacerbation or mortality. The...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

TachoSil regulatory update

The European Commission approved an expanded label for Takeda’s TachoSil to include supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery. The human fibrinogen and thrombin hemostatic surgical patch is...